Elicio Therapeutics (ELTX) Net Income towards Common Stockholders (2020 - 2026)
Elicio Therapeutics (ELTX) reported Net Income towards Common Stockholders of -$10.9 million for Q1 2026, down 1.4% on a YoY basis from -$11.0 million in Q1 2025, and down 18.23% quarter-over-quarter from -$9.2 million in Q4 2025.
Elicio Therapeutics (ELTX) Net Income towards Common Stockholders (2020 - 2026) Analysis & Trends
Elicio Therapeutics has reported Net Income towards Common Stockholders for 7 years, with the latest figure at -$10.9 million in Q1 2026.
- For the quarter ending Q1 2026, Net Income towards Common Stockholders fell 1.4% year-over-year to -$10.9 million; the trailing twelve-month figure through Mar 2026 stood at -$38.4 million (up 15.64% YoY), and the FY2025 full-year result was -$38.8 million, up 14.51% from the prior year.
- Net Income towards Common Stockholders for Q1 2026 stood at -$10.9 million, down from -$9.2 million in the prior quarter.
- The five-year high for Net Income towards Common Stockholders was -$6.0 million in Q4 2022, with the low at -$14.5 million in Q1 2022.
- Historically, Net Income towards Common Stockholders has averaged -$9.7 million across 5 years, with a median of -$10.1 million in 2025.
- The largest YoY upside for Net Income towards Common Stockholders was 59.99% in 2022 against a maximum downside of 140.99% in 2022.
- Elicio Therapeutics' Net Income towards Common Stockholders stood at -$6.0 million in 2022, then tumbled by 55.37% to -$9.3 million in 2023, then slumped by 47.12% to -$13.7 million in 2024, then jumped by 33.05% to -$9.2 million in 2025, then dropped by 18.23% to -$10.9 million in 2026.
- The last three Net Income towards Common Stockholders figures came in at -$10.9 million (Q1 2026), -$9.2 million (Q4 2025), and -$8.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | -13.56 Mn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 2.50 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | -3.63 Mn |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | -56.48 Mn |
| 10 | Elicio Therapeutics | 270.44 Mn | 255.50 Mn | - | -10.85 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -10.85 Mn |
| Dec 31, 2025 | -9.18 Mn |
| Sep 30, 2025 | -8.27 Mn |
| Jun 30, 2025 | -10.12 Mn |
| Mar 31, 2025 | -10.70 Mn |
| Dec 31, 2024 | -13.71 Mn |
| Sep 30, 2024 | -10.30 Mn |
| Jun 30, 2024 | -10.84 Mn |
| Mar 31, 2024 | -10.13 Mn |
| Dec 31, 2023 | -9.32 Mn |
| Sep 30, 2023 | -10.53 Mn |
| Jun 30, 2023 | -8.45 Mn |
| Mar 31, 2023 | -8.14 Mn |
| Dec 31, 2022 | -6.00 Mn |
| Sep 30, 2022 | -6.84 Mn |
| Jun 30, 2022 | -7.30 Mn |
| Mar 31, 2022 | -14.49 Mn |
| Dec 31, 2021 | 14.63 Mn |
| Sep 30, 2021 | -15.76 Mn |
| Jun 30, 2021 | -18.24 Mn |